Zoetis Inc. (NYSE:ZTS) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Zoetis Inc. (NYSE:ZTS) have been assigned a consensus recommendation of “Hold” from the fifteen analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $141.25.

Several equities analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Piper Sandler reissued a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Citigroup assumed coverage on shares of Zoetis in a report on Wednesday, April 15th. They issued a “buy” rating and a $145.00 price target for the company. Bank of America upped their target price on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research note on Friday.

Zoetis Stock Performance

Shares of Zoetis stock opened at $82.80 on Monday. The firm has a fifty day moving average of $118.49 and a two-hundred day moving average of $123.70. The stock has a market capitalization of $34.83 billion, a price-to-earnings ratio of 13.73, a PEG ratio of 1.34 and a beta of 0.87. Zoetis has a 52 week low of $81.10 and a 52 week high of $172.23. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 61.97%. The business’s revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities research analysts predict that Zoetis will post 7.01 EPS for the current year.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: JPMorgan lowered its price target on Zoetis from $190 to $130, but kept an overweight rating, implying the stock still has meaningful upside from current levels. Benzinga report on JPMorgan target cut
• Neutral Sentiment: Some analysts remain constructive overall, with recent coverage still showing buy/overweight views and price targets well above the current share price, suggesting longer-term confidence despite near-term pressure.
• Negative Sentiment: Zoetis missed Q1 earnings and revenue estimates, which immediately hurt sentiment around the stock.
• Negative Sentiment: The company cut its FY2026 guidance after seeing weaker U.S. companion animal demand and pricing pressure, raising concerns that pet owners are spending less on veterinary care and premium products. Benzinga report on weak pet care demand
• Negative Sentiment: Media coverage described the earnings release as a sharp disappointment, with reports highlighting a steep selloff after investors reacted to the softer outlook.
• Negative Sentiment: Ademi LLP announced a securities fraud investigation into Zoetis, adding another overhang for shares as investors assess potential legal risk.

Hedge Funds Weigh In On Zoetis

A number of large investors have recently modified their holdings of ZTS. Oslo Pensjonsforsikring AS bought a new position in Zoetis in the 1st quarter valued at about $185,000. Baader Bank Aktiengesellschaft raised its holdings in Zoetis by 1.6% in the 1st quarter. Baader Bank Aktiengesellschaft now owns 35,012 shares of the company’s stock valued at $4,139,000 after acquiring an additional 548 shares during the period. Cassaday & Co Wealth Management LLC bought a new position in Zoetis in the 1st quarter valued at about $28,000. Commerzbank Aktiengesellschaft FI raised its holdings in Zoetis by 41.8% in the 1st quarter. Commerzbank Aktiengesellschaft FI now owns 15,709 shares of the company’s stock valued at $1,857,000 after acquiring an additional 4,628 shares during the period. Finally, Meeder Asset Management Inc. raised its holdings in Zoetis by 69.2% in the 1st quarter. Meeder Asset Management Inc. now owns 45,286 shares of the company’s stock valued at $5,353,000 after acquiring an additional 18,519 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.